Published: Oct. 9, 2013
Updated: Oct. 9, 2013
Reporters & producers can visit Duke Medicine News and Communications for contact information.
James Abbruzzese, MD, will become the Chief of the Duke Division of Medical Oncology and Associate Director for Clinical Research for the Duke Cancer Institute (DCI), effective November 11, 2013.
Dr. Abbruzzese is a leading expert in the clinical study and treatment of pancreatic cancer, and his management experience and vision for clinical research and the Division will substantially support cancer care and research at Duke. Currently, he holds the Waun Ki Hong Distinguished Chair in Translational Oncology and he is chairman of the Department of Gastrointestinal Medical Oncology and Digestive Diseases at the University of Texas M. D. Anderson Cancer Center in Houston.
He earned his medical degree with honors from the University of Chicago Pritzker School of Medicine and completed his residency in Internal Medicine at Johns Hopkins Hospital. He also completed clinical fellowships in Infectious Diseases at the Johns Hopkins and in Medical Oncology and Medical Oncology Research Laboratory of Neoplastic Disease Mechanisms at the Dana-Farber Cancer Institute of Harvard Medical School. He has spent most of his professional career at M.D. Anderson, where he rose through the ranks to his current leadership positions as Chairman of the Department of Gastrointestinal Medical Oncology and Associate Vice-Provost for Clinical Research.
Among his many accomplishments, Dr,. Abbruzzese is a Fellow of the American College of Physicians and Fellow of the American Society of Clinical Oncology. He has co-authored more than 400 research publications and currently serves as Chair of the Clinical Trials and Translational Research Advisory Committee of the National Cancer Institute.
As associate director for clinical research in the Duke Cancer Institute, he will guide and direct DCI’s 13 oncology disease-based clinical research groups, and he will be responsible for the clinical trials operation that encompasses more than 1,000 open trials with an average annual accrual of 6,000 patients. He also will lead the Division of Medical Oncology, a major partner of the DCI. The Division has 58 full-time, regular-rank faculty members with substantial clinical activities and a current research portfolio of $76 million in funding, 111 grants – of which 36 are NIH funded – and 188 active clinical trials.
Dr. Abbruzzese will succeed Jeffrey Crawford, MD, who has served as chief of the Division since 2004, and Christopher Willett, MD, who has served as Associate Director for Clinical Research since 2011. We are grateful to both gentlemen for their leadership, impact on the development of the DCI, and ongoing commitment to cancer care and research excellence.